Association of serum 25-hydroxyvitamin D concentrations with all-cause and cause-specific mortality among individuals with gout and hyperuricemia

Liu, Ke; Lu, Xuanni; Wang, Anqi; Chen, Weiwei; Chen, Ying; Li, Jiayu; Sun, Xiaohui; Huang, Lin; He, Zhixing; Wen, Chengping; Mao, Yingying; Ye, Ding

doi:10.1186/s12937-024-00992-8

Table 2 HRs (95% CIs) for mortality according to serum 25(OH)D concentrations among participants with gout

From: Association of serum 25-hydroxyvitamin D concentrations with all-cause and cause-specific mortality among individuals with gout and hyperuricemia

	Serum 25(OH)D concentrations (nmol/L)					Per One-Unit Increment in Natural Log-Transformed 25(OH)D
	< 25.00	25.00–49.99	50.00–74.99	≥ 75.00	P_trend^a	Per One-Unit Increment in Natural Log-Transformed 25(OH)D
All-cause mortality
Number of deaths (%)	23 (35.90)	65 (23.00)	84 (21.90)	76 (17.40)
Model 1	1.00	0.57 (0.33,0.97), 0.037	0.47 (0.29,0.77), 0.002	0.33 (0.19,0.57), < 0.001	< 0.001	0.56 (0.42,0.75), < 0.001
HR (95% CI), P-value	1.00	0.57 (0.33,0.97), 0.037	0.47 (0.29,0.77), 0.002	0.33 (0.19,0.57), < 0.001	< 0.001	0.56 (0.42,0.75), < 0.001
Model 2	1.00	0.61 (0.34,1.12), 0.109	0.37 (0.21,0.64), < 0.001	0.23 (0.14,0.39), < 0.001	< 0.001	0.42 (0.33,0.53), < 0.001
HR (95% CI), P-value	1.00	0.61 (0.34,1.12), 0.109	0.37 (0.21,0.64), < 0.001	0.23 (0.14,0.39), < 0.001	< 0.001	0.42 (0.33,0.53), < 0.001
Model 3	1.00	0.67 (0.42,1.09), 0.109	0.46 (0.30,0.72), 0.001	0.30 (0.19,0.45), < 0.001	< 0.001	0.45 (0.37,0.56), < 0.001
HR (95% CI), P-value	1.00	0.67 (0.42,1.09), 0.109	0.46 (0.30,0.72), 0.001	0.30 (0.19,0.45), < 0.001	< 0.001	0.45 (0.37,0.56), < 0.001
CVD mortality
Number of deaths (%)	11 (17.20)	21 (7.40)	22 (5.70)	22 (5.00)
Model 1	1.00	0.43 (0.19,0.93), 0.033	0.28 (0.12, 0.67), 0.004	0.21 (0.09,0.51), 0.001	0.013	0.46 (0.25,0.84), 0.011
HR (95% CI), P-value	1.00	0.43 (0.19,0.93), 0.033	0.28 (0.12, 0.67), 0.004	0.21 (0.09,0.51), 0.001	0.013	0.46 (0.25,0.84), 0.011
Model 2	1.00	0.48 (0.18,1.23), 0.127	0.25 (0.10,0.61), 0.002	0.16 (0.06,0.42), < 0.001	0.002	0.39 (0.22,0.66), 0.001
HR (95% CI), P-value	1.00	0.48 (0.18,1.23), 0.127	0.25 (0.10,0.61), 0.002	0.16 (0.06,0.42), < 0.001	0.002	0.39 (0.22,0.66), 0.001
Model 3	1.00	0.58 (0.19,1.73), 0.330	0.32 (0.12,0.81), 0.016	0.21 (0.08,0.57), 0.002	0.003	0.39 (0.23,0.67), 0.001
HR (95% CI), P-value	1.00	0.58 (0.19,1.73), 0.330	0.32 (0.12,0.81), 0.016	0.21 (0.08,0.57), 0.002	0.003	0.39 (0.23,0.67), 0.001
Cancer mortality
Number of deaths (%)	4 (6.20)	13 (4.60)	13 (3.40)	19 (4.30)
Model 1	1.00	0.56 (0.18,1.76), 0.320	0.49 (0.17,1.42), 0.187	0.64 (0.23,1.81), 0.400	0.927	0.88 (0.46,1.69), 0.693
HR (95% CI), P-value	1.00	0.56 (0.18,1.76), 0.320	0.49 (0.17,1.42), 0.187	0.64 (0.23,1.81), 0.400	0.927	0.88 (0.46,1.69), 0.693
Model 2	1.00	0.74 (0.20,2.81), 0.664	0.46 (0.11,1.87), 0.275	0.58 (0.20,1.64), 0.302	0.574	0.68 (0.41,1.11), 0.124
HR (95% CI), P-value	1.00	0.74 (0.20,2.81), 0.664	0.46 (0.11,1.87), 0.275	0.58 (0.20,1.64), 0.302	0.574	0.68 (0.41,1.11), 0.124
Model 3	1.00	0.85 (0.20,3.66), 0.825	0.47 (0.09,2.34), 0.354	0.60 (0.21,1.77), 0.356	0.550	0.68 (0.42,1.11), 0.126
HR (95% CI), P-value	1.00	0.85 (0.20,3.66), 0.825	0.47 (0.09,2.34), 0.354	0.60 (0.21,1.77), 0.356	0.550	0.68 (0.42,1.11), 0.126

Model 1: Non-adjusted (n = 1169)
Model 2: Adjusted for age, gender, race/ethnicity, and survey cycle (n = 1169)
Model 3: Adjusted for age, gender, race/ethnicity, survey cycle, education level, PIR, BMI, smoking status, alcohol consumption, hypertension, diabetes, and uric acid (n = 1152)
^aP value for trend was tested according to the statistical significance of the median value for category variables

Back to article page

ISSN: 1475-2891

Contact us

General enquiries: journalsubmissions@springernature.com

Nutrition Journal

Contact us